Maternal TLR4 and NOD2 gene variants, pro-inflammatory phenotype and susceptibility to early-onset preeclampsia and HELLP syndrome

PLoS ONE

Volumn 3, Issue 4, 2008, Pages

  van Rijn, Bas B ^a   Franx, Arie ^b   Steegers, Eric A P ^c   de Groot, Christianne J M ^d   Bertina, Rogier M ^e   Pasterkamp, Gerard ^a   Voorbij, Hieronymus A M ^a   Bruinse, Hein W ^a   Roest, Mark ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b CPRLab   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d MEDICAL CENTER HAAGLANDEN   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; FIBRINOGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; TOLL LIKE RECEPTOR 4; VON WILLEBRAND FACTOR; ENDOTOXIN; NOD2 PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HELLP SYNDROME; HUMAN; HYPERTENSION; INFLAMMATION; INNATE IMMUNITY; LINKAGE ANALYSIS; MAJOR CLINICAL STUDY; MATERNAL AGE; MATERNAL DISEASE; MUTATION RATE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PHENOTYPE; PREECLAMPSIA; PRIMIPARA; PROTEIN BLOOD LEVEL; ALLELE; BIOLOGICAL MODEL; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PREGNANCY;

ADULT; ALLELES; ENDOTOXINS; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HELLP SYNDROME; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; NOD2 SIGNALING ADAPTOR PROTEIN; PRE-ECLAMPSIA; PREGNANCY; TOLL-LIKE RECEPTOR 4; VARIATION (GENETICS);

EID: 44849130837     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001865     Document Type: Article

References (54)

1. Redman CW, Sargent IL (2005) Latest advances in understanding preeclampsia. Science 308: 1592-1594.
2. WHO (2005) Make Every Mother and Child Count. Geneva: World Health Report.
3. Borzychowski AM, Sargent IL, Redman CW. (2006) Inflammation and preeclampsia. Semin Fetal Neonatal Med 11: 309-316.
4. Terrote DA, Rinehart BK, May WI, Moore A, Magann EF, et al. (2000) Leukocytosis is proportional to HELLP2 syndrome severity: evidence for an inflammatory form of preeclampsia. South Med J, 93:768-711.
5. McMaster MT, Bass KE, Fisher SJ (1994) Human trophoblast invasion. Autocrine control and paracrine modulation. Awnn NY Acad Sci 734: 122-131.
6. Lafayette RA, Druzin M, Sibley R, Derby G, Malik T, et al, (1998) Nature of glomerular dysfunction in preeclampsia. Kidney Int 54: 1210-1249.
7. Visser N, van Rijn BB, Rijkers GT, Franx A, Bruinse HW (2007) Inflammatory changes in preeclampsia: current understanding of the maternal innate and adaptive immune response. Obstet Gynecol Surv 62: 191-201.
8. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, et al. (2004) Interleukin-10 and related cytokines and receptors. Annu Rev Immunol. 22: 929-979.
9. beutler B, Poltorak A (2001) Sepsis and evolution of the innate immune response. Crit Care Med 29: S2-6, dismission S6-7.
10. Yang IA, Fong KM, Holgate ST, Holloway JW (2006) The role of Toll-like receptors and related receptors of the innate, immune system in asthma. Curr Opin Allergy Clin Immunol 6:23-28.
11. Van Heel DA, McGovern DP, Jewell DP (2001) Crohn's disease: genetic susceptibility, bacteria, and innate immunity. Lancet 357: 1902-1904.
12. Faas MM, Schuiling GA, Baller JF, Visscher CA, Bakker WW (1991) A new animal model for human preeclampsia: ultra-low-dose endotoxin infusion in pregnant rats. Am J Obstet Gynecol 171: 158-164.
13. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, et al. (2000) TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 25: 187-191.
14. Gaya DR, Russell RK, Nimmo ER, Satsangi J (2006) New genes in inflammatory bowel disease: lessons for complex diseases? Lancet 367: 1271-1281.
15. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, et al. (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411: 599-603.
16. Crider KS, Whitehead N, Buus RM (2005) Genetic variation associated with preterm birth: a HuGE review. Genet Med 7: 593-604.
17. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F et al. (2002) Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 347: 185-192.
18. Sikkema JM, Franx A, Bruinse HW, van der Wijk NG, de Valk HW, et al. (2002) Placental pathology in early onset pre-eclampsia and intra-uterine growth restriction in women with and without thrombophilia. Placenta 23: 337-342.
19. van Rijn BB, Hoeks LB, Bois ML, Franx A, Bruinse HW (2006) Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia. Am J Obstet Gynecol 195: 723-728.
20. De Groot CJ, Bloemenkamp KW, Duvekot EJ, Helmerhorst FM, Bertina RM, et al. (1999) Preeclampsia and genetic risk factors for thrombosis: a case-control study. Am J Obstet Gynecol 181: 975-980.
21. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM (2001) The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 20: IX-XIV.
22. Sibai BM, Taslimi MM, el-Nazer A, Amon E, Mabie BC, et al. (1986) Maternal-perinatal outcome associated with the syndrome of hemolysis, elevated liver enzymes, and low platelets in severe preeclampsia-eclampsia. Am J Obstet Gynecol 153: 501-509.
23. Kloosterman GJ (1969) [Intrauterine growth and intrauterine growth curves]. Ned Tijdschr Verloskd Gynaecol 69: 349-365.
24. van Rijn BB, Roest M, Franx A, Bruinse HW, Voorbij HA (2004) Sirigle step high-throughput determination of Toll-like receptor 4 polymorphisms. J Immunol Methods 289: 81-87.
25. Hulstein JJ, van Runnard Heimel PJ, Franx A, Lenting PJ, Bruinse HW, et al. (2006) Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome. J Thromb Haemost 4: 2569-2575.
26. D'Agostino RB Sr., Grundy S, Sullivan LM, Wilson P (2001) Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. Jama 286: 180-187.
27. Freeman DJ, McManus F, Brown EA, Cherry L, Norrie J, et al. (2004) Short- and long-term changes in plasma inflammatory markers associated with preeclampsia. Hypertension 44: 708-714.
28. Beutler B, Jiang Z, Georgel P, Crozat K, Croker B, et al. (2006) Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu Rev Immunol 24: 353-389.
29. Bulut Y, Faure E, Thomas L, Karahashi H, Michelsen KS, et al. (2002) Chlamydial heat shock protein 60 activates macrophages and endothelial cells through Toll-like receptor 4 and MD2 in a MyD88-dependent pathway. J Immunol 168: 1435-1440.
30. Kurt-June EA, Popova L, Kwinn L, Haynes LM, Jones LP, et al. (2000) Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 1: 398-401.
31. Krishnegowda G, Hajjar AM, Zhu J, Douglass EJ, Uematsu S, et al. (2005) Induction of proinflammatory responses in macrophages by the glycosylpho-sphatidylinositols of Plasmodium falciparum: cell signaling receptors, glycosyl-phosphatidylinositol (GPI) structural requirement, and regulation of GPI activity. J Biol Chem 280: 8606-8616.
32. Rallabhandi P, Bell J, Boukhvalova MS, Medvedev A, Lorenz E, et al. (2006) Analysis of TLR4 polymorphic variants: new insights into TLR4/ MD-2/CD14 stoichiometry, structure, and signaling. J Immumol 177: 322-332.
33. Mockenhaupt FP, Cramer JP, Hamann L, Stegemann MS, Eckert J, et al. (2006) Toll-like receptor (TLR) polymorphisms in African children: Common TLR-4 variants predispose to severe malaria. Proc Natl Acad Sci USA 103: 177-182.
34. Boggess KA, Lieff S, Murtha AT, Moss K, Beck J, et al. (2003) Maternal periodontal disease is associated with an increased risk for preeclampsia. Obstet Gynecol 101: 227-231.
35. Arechavaleta-Velasco F, Ma Y, Zhang J, McGrath CM, Parry S (2006) Adenoassociated virus-2 (AAV-2) causes trophoblast dysfunction, and placental AAV-2 infection is associated with preeclampsia. Am J Pathol 168: 1951-1959.
36. Stepan H, Faber R (2006) Elevated sFlt1 level and preeclampsia with parvovirus-induced hydrops. N Engl J Med 354: 1857-1858.
37. von Dadelszen P, Magee LA, Krajden M, Alasaly K, Popovska V, et al. (2003) Levels of antibodies against cytomegalovirus and Chlamydophila pneumoniae are increased in early onset pre-eclampsia. Bjog 110: 725-730.
38. Goulis DG, Chappell L, Gibbs RG, Williams D, Dave JR, et al (2005) Association of raised titres of antibodies to Chlamydia pneumoniae with a history of pre-eclampsia. Bjog 112: 299-305.
39. Mockenhaupt FP, Hamann L, von Gaertner C, Bedu-Addo G, von Kleinsorgen C, ect al. (2006) Common polymorphisms of toll-like receptors 4 and 9 are associated with the clinical manifestation of malaria during pregnancy. J Infect Dis 194: 184-188.
40. Cunningham DS, Christie TL, Evans EE, McCaul JF (1993) Effect of the HELLP symdrome on maternal immune function. J Reprod Med 38: 459-464.
41. Martin JN Jr., Blake PG, Perry KG Jr., McCaul JF, Hess LW, et al. (1991) The natural history of HELLP syndrome: patterns of disease progression; and regression. Am J Obstet Gynecol 164: 1500-1509; discussion 1509-1513.
42. van Runnard Heimel PJ, Huisjes AJ, Franx A, Koopman C, Bots ML, et al. (2006) A randomised placebo-controlled trial of prolonged prednisolone administration to patients with HELLP syndrome remote from term. Eur J Obstet Gynecol Reprod Biol 128: 137-193.
43. Ohashi K, Bukart V, Flohe S, Kolb H (2000) Cutting edge: beat shock protein 60 is a putative endogenous ligand oftbe toll-like receptor-4 complex. J Immunol 164: 558-561.
44. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, et al. (2001) The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 276: 10229-10233.
45. Matzinger P (2002.) The danger model: a renewed sense of self. Science 296: 301-305.
46. Levine RJ, Qian C, Leshane ES, Yu KF, England LJ, et al. (2004) Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. Am J Obstet Gynecol 190: 707-713.
47. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, et al. (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350: 672-683.
48. Kim YM, Romero R, Oh SY, Kim CJ, Kilburn BA, et al. (2005) Toll-like receptor 4: a potential link between "danger signals," the innate immune system, and preeclampsia? Am J Obstet Gynecol 193: 921-927.
49. Watanabe T, Kitani A, Murray PJ, Strober W (2004) NOD2 is a negative regulator of Toll-like receptor 2-mediated T. helper type 1 responses. Nat Immunol 5: 800-808.
50. Costello MJ, Joyce SK, Abrahams VM (2007) NOD protein expression and function in first trimester trophoblast cells. Am J Reprod Immunol 57: 67-80.
51. Goddard KA, Tromp G, Romero R, Olson JM, Lu Q et al. (2007) Candidate-gene association study of mothers with pre-eclampsia, and their infants, analyzing 775 SNPs in 190 genes. Hum Hered 63: 1-16.
52. Ridker PM, Brown NJ, Vaughan DE, Harrison DC, Mehta JL (2004) Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 109: IV6-19.
53. Smith GC, Pell JP, Walsh D (2001) Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. Lancet 357: 2002-2006.
54. Cordeil HJ, Clayton DG (2005) Genetic association studies. Lancet 366: 1121-1131.